SecBot SecBot
8-K ·Filed May 22, 2026

ENSCW

Ensysce Biosciences, Inc.
BEARISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001493152-26-025061
8-K context-dependent: Items 3.01
Actionable Insight ▼ Bearish

Monitor the compliance plan submission by July 6, 2026. If the plan is rejected or the company fails to regain compliance within the extension period, warrants will likely be delisted from Nasdaq and trade over-the-counter with minimal liquidity. Given the small market cap and early-stage nature, a capital raise or reverse split may be attempted to restore equity — watch for related filings.

DirectionBearish
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

Ensysce Biosciences received a Nasdaq delisting notice on May 21, 2026 for failing to meet the $2.5M stockholders' equity requirement as of March 31, 2026. The company has 45 days (by July 6, 2026) to submit a compliance plan, with a possible 180-day extension. Failure to regain compliance will result in delisting from Nasdaq.

Key Facts

  • Nasdaq delisting notice received May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement (Rule 5550(b)(1))
  • Deadline to submit compliance plan: July 6, 2026 (45 days from notice)
  • If plan accepted, extension up to 180 days from May 21, 2026 to regain compliance
  • If plan rejected, company may appeal to Nasdaq Hearings Panel
  • No assurance that plan will be accepted or compliance can be regained
  • Ticker ENSCW is a warrant, not common stock; common stock (ENSC) trades on Nasdaq

Financial Impact

Delisting risk is binary; if delisted, warrants (ENSCW) lose exchange listing and liquidity severely dries up

stockholders_equitylisting_statusliquidity

Risk Factors

  • Delisting from Nasdaq would severely reduce liquidity and institutional ownership
  • Company may need to raise dilutive capital at distressed levels to restore equity compliance
  • If appeal fails, warrants (ENSCW) could become worthless or trade at pennies
  • Uncertainty around ability to regain compliance within timeline

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001493152-26-025061
Document: 0001493152-26-025061-index-headers.html0001493152-26-025061
Document: 0001493152-26-025061-index.html0001493152-26-025061
Document: 0001493152-26-025061.txt0001493152-26-025061
5 reports for ENSCW
Performance horizon
Filters
Rows
Reports for ENSCW — sortable, filterable
TypeNow
Jun 4, 2026
20w ago
S-3
BEARISH ★ 6/10
—awaiting T+20——
May 22, 2026
22w ago
8-K
BEARISH ★ 7/10
—awaiting T+20——
May 15, 2026
23w ago
8-K
BEARISH ★ 7/10
—awaiting T+20——
Apr 3, 2026
29w ago
8-K
NEUTRAL ★ 3/10
—awaiting T+20——
Mar 30, 2026
30w ago
8-K
NEUTRAL ★ 4/10
—awaiting T+20——
Showing 5 of 5

US Market Status

Market Closed — Opens Wed (16h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 22, 2026